Hepatx was founded by Eric Schuur in 2015.

Who are Hepatx's investors?

Hepatx's investors include iSelect Fund, Sand Hill Angels, StartX, Y Combinator, Palapa Ventures, SP Investment Fund.

Where is Hepatx headquartered?

Hepatx is headquartered in San Francisco, US.

Hepatx

YC S18

San Francisco, US · Founded 2015 · 4 employees · 6 known investors

Find your way into Hepatx

Paths you didn't know you had: your email and LinkedIn already hold routes to the Hepatx team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.

Also known as Hepatx Corporation

Biotech Healthtech Medical DevicesUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S18)

Hepatx was founded in 2015 by Eric Schuur.

Eric Schuur Chief Executive Officer, Co-founderWith over 25 years in biopharma and medical devices, he has held leadership roles in regenerative medicine and cell therapy development, including work on oncolytic virus development at Calydon and clinical program leadership at Asthmatx, and has authored numerous peer-reviewed publications and patent applications.

Mark Chao

Investors · 6

iSelect Fundlisted by iSelect FundSt. Louis · $250K – $2M

How we know: iSelect Fund's portfolio page · Not right? Tell us

Sand Hill Angelslisted by Sand Hill AngelsMenlo Park · $50K – $2M

StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Palapa Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

SP Investment Fundreported

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 7

UnimaUnima makes portable diagnostic tests that deliver disease identification at the point of care within 15 minutes at low cost, enabling rapid detection and monitoring of infectious diseases.

Entelexo BiotherapeuticsEntelexo develops engineered exosome therapeutics for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company uses a proprietary platform to design exosomes that communicate with multiple diseased cell types simultaneously, replacing traditional single-target treatments.

IsablIsabl develops whole genome and transcriptome sequencing technology for cancer diagnosis, delivering comprehensive genomic profiling and treatment options to physicians and research teams. The company provides rapid cancer diagnostic tests in clinically relevant timeframes to improve outcomes for cancer patients globally.

Science ExchangeScience Exchange provides operational infrastructure for life sciences R&D, connecting organizations, suppliers, and workflows to streamline contracting, compliance, onboarding, and financial coordination across the research ecosystem.

InvitrisInvitris develops cell-free protein synthesis platforms that enable rapid design, expression, and scalable production of complex proteins for biopharmaceuticals, industrial biotechnology, and agriculture.

TheratomeBioTheratome Bio is a regenerative medicine company using artificial intelligence to develop secretome-based therapeutics that address tissue repair and disease. The company focuses on organ transplant preservation and dry eye disease treatments.

Haya TherapeuticsHAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.

Companies working in the same space as Hepatx.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2019	$225K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2017	$149.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure

HepaTx Corporation

Frequently asked questions

What does Hepatx do?: HepaTx develops stem cell-based hepatocyte therapies for liver disease treatment as an alternative to organ transplantation. The company targets niche liver disease indications including alpha-1 antitrypsin deficiency, phenylketonuria, and non-alcoholic steatohepatitis.
Who founded Hepatx?: Hepatx was founded by Eric Schuur in 2015.
Who are Hepatx's investors?: Hepatx's investors include iSelect Fund, Sand Hill Angels, StartX, Y Combinator, Palapa Ventures, SP Investment Fund.
Where is Hepatx headquartered?: Hepatx is headquartered in San Francisco, US.